Illumina (ILMN) Names Sanjay Chikarmane As Senior Vice President And General Manager Of Enterprise Informatics

SAN DIEGO--(BUSINESS WIRE)--Illumina Inc. (NASDAQ:ILMN) today announced that Sanjay Chikarmane has been named Senior Vice President and General Manager of Illumina's Enterprise Informatics business. Chikarmane will lead the development and commercialization of products and services aimed at turning genomic data into actionable information for researchers and clinicians. He will report to Illumina President, Francis deSouza.

"Sanjay is an excellent addition to Illumina's leadership team and will be instrumental in growing our enterprise informatics business, defining our software development processes and service delivery architecture that will be used across all of Illumina."

"Given the growing data intensive demands of the genomics market, we felt it critical to bring in a group leader dedicated to driving our informatics strategy," said Francis deSouza, President of Illumina. "Sanjay is an excellent addition to Illumina's leadership team and will be instrumental in growing our enterprise informatics business, defining our software development processes and service delivery architecture that will be used across all of Illumina."

Nick Naclerio who led the acquisition of NextBio and served as the founding General Manager of the Enterprise Informatics business unit will return to the full-time role of Senior Vice President of Corporate Development.

Chikarmane joins Illumina with more than 20 years of experience in enterprise software at companies including HP, BEA Systems and most recently, SAP. Through his career, he has held a variety of leadership roles in enterprise software, including general management, go-to-market, product management and product development, during which he has successfully created and scaled several market leading products. While at SAP, Chikarmane oversaw several key products including industry solutions for big data analytics on the HANA platform, cloud business networks, data management and middleware, including their adoption by top customers.

Chikarmane holds a Bachelor of Technology degree in Electrical Engineering from the Indian Institute of Technology (IIT), Bombay, India and a Master of Science in Computer Engineering from Syracuse University.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Contacts

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
[email protected]
or
Media:
Jennifer Temple, 858-882-6822
[email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.

The series A gives ex-Roche VP George Garibaldi a chance to realize the potential of assets that fell by the wayside at the Swiss pharma.